Atherosclerotic renovascular disease: A clinical practice document by the European Renal Best Practice (ERBP) board of the European Renal Association (ERA) and the Working Group Hypertension and the Kidney of the European Society of Hypertension (ESH)


Creative Commons License

Sarafidis P. A., Theodorakopoulou M., Ortiz A., Fernandez-Fernandez B., Nistor I., Schmieder R., ...More

Nephrology Dialysis Transplantation, vol.38, no.12, pp.2835-2850, 2023 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Review
  • Volume: 38 Issue: 12
  • Publication Date: 2023
  • Doi Number: 10.1093/ndt/gfad095
  • Journal Name: Nephrology Dialysis Transplantation
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CAB Abstracts, MEDLINE, Veterinary Science Database
  • Page Numbers: pp.2835-2850
  • Keywords: angioplasty, atherosclerotic renovascular disease, epidemiology, renal artery stenosis, revascularization
  • Hacettepe University Affiliated: Yes

Abstract

Atherosclerotic renovascular disease (ARVD) is the most common type of renal artery stenosis. It represents a common health problem with clinical presentations relevant to many medical specialties and carries a high risk for future cardiovascular and renal events, as well as overall mortality. The available evidence regarding the management of ARVD is conflicting. Randomized controlled trials failed to demonstrate superiority of percutaneous transluminal renal artery angioplasty (PTRA) with or without stenting in addition to standard medical therapy compared with medical therapy alone in lowering blood pressure levels or preventing adverse renal and cardiovascular outcomes in patients with ARVD, but they carried several limitations and met important criticism. Observational studies showed that PTRA is associated with future cardiorenal benefits in patients presenting with high-risk ARVD phenotypes (i.e. flash pulmonary oedema, resistant hypertension or rapid loss of kidney function). This clinical practice document, prepared by experts from the European Renal Best Practice (ERBP) board of the European Renal Association (ERA) and from the Working Group on Hypertension and the Kidney of the European Society of Hypertension (ESH), summarizes current knowledge in epidemiology, pathophysiology and diagnostic assessment of ARVD and presents, following a systematic literature review, key evidence relevant to treatment, with an aim to support clinicians in decision making and everyday management of patients with this condition.